Posted by Michael Wonder on 21 Oct 2023
Rezolute receives Priority Medicines (PRIME) eligibility from EMA for enhanced regulatory support of RZ358 in congenital hyperinsulinism
17 October 2023 - PRIME eligibility granted based on key positive data from the Phase 2B (RIZE) study and current unmet medical need in congenital hyperinsulinism.
Rezolute today announced that the EMA has granted Priority Medicines (PRIME) eligibility to RZ358 for the treatment of congenital hyperinsulinism.
